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Abstract 
The 28 amino acid hormone, ghrelin has been found to have various effects on metabolism. This 
review will focus on the pathways integrated into ghrelin’s effect within the hypothalamus, pancreas 
and adipocytes. The identification of molecules and pathways that regulate ghrelin mediated lipid 
retention could establish new mechanisms underlying cellular energy homeostasis. The impact of 
acyl-ghrelin on glucose metabolism and lipid homeostasis may allow for novel preventative or early 
intervention therapeutic strategies to treat obesity related type 2 diabetes and associated metabolic 
dysfunction.  
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1 Introduction 
Type 2 diabetes mellitus (T2DM) and obesity are both chronic conditions associated with significant 
morbidity and mortality predominantly from associated chronic diseases. The World Health 
Organisation (WHO) states that obesity is a global epidemic, with over 1.9 billion obese adults. 
Obesity results from the dysregulation of energy expenditure resulting in an accumulation of white 
adipose tissue due to adipogenesis or lipid retention 1. Therefore, the function of adipocytes, which 
includes the secretion of various hormones linked to the modulation of metabolism, is central to the 
development of obesity. A key hormone of interest, that is known to regulate cell proliferation and 
lipid retention, is the gastrointestinal peptide ghrelin 2. The focus of this article is to review the 
mechanism(s) underlying ghrelin mediated lipid retention in adipocytes and its relevance to the 
aetiology of T2DM. The identification of new molecules modulating ghrelin mediated lipid retention 
in adipose tissue may be a therapeutic strategy for improving glucose homeostasis associated with 
obesity and T2DM. 
2 Ghrelin 
In 1999, Masayasu Kojima first described a 28 amino acid peptide hormone located in the stomach, 
with a distinctive N-octanoylated serine 3 residue 2. This peptide was named ‘ghrelin’, from the Latin 
word ‘Ghre’ which means ‘grow’ due to its role as a growth hormone releasing peptide 2, 3. The novel 
peptide was isolated from the gut of both human and rat as the endogenous ligand of the growth 
hormone secretagogue receptor (GHS-R) 4. GHS-R is transcribed in humans from the growth 
hormone receptor 1 (GHR1) gene, which encodes the full length functional receptor (GHS-R1α) and a 
splice variant truncated non-functional isoform (GHS-R1β) 5, 6. GHS-R1α mRNA is expressed at low 
levels over a wide tissue distribution but it predominantly expressed in the anterior pituitary gland 5. 
The highest levels of ghrelin are secreted from the X/A- like cells of the oxyntic glands located in the 
gastric fundus, with lower levels widely distributed throughout the body 7, 8. Ghrelin is secreted 
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direct into the local gastric circulation and transported to the brain directly, requiring it to either 
cross the blood-brain barrier via a saturated transport system or via the blood stream to enter areas 
of the brain that are not protected by the blood brain barrier 9. Ghrelin also modulates the 
hypothalamic arcuate nucleus (ARC), in an indirect manner, via activation of the vagus nerve and 
brain stem nuclei 9, 10. Ghrelin circulates in two major forms; acylated (approximately 5% of total 
ghrelin) and desacyl (95% of total ghrelin) 11. Previous work has demonstrated that the protein 
coding gene, membrane bound O-acyltransferase 4 (MBOAT4) is vital in the activation of ghrelin 12. 
The human gene, MBOAT4 is located on chromosome 8 (8p12) and contains 6 exons. MBOAT4 
transcribes a protein that was later termed ghrelin O-acyltransferase (GOAT), as this is the only 
enzyme known to post translationally acylate ghrelin. Both forms of ghrelin are observed to cross 
the barrier in a blood to brain direction. However, desacyl-ghrelin had reduced ability in crossing the 
barrier in a brain-blood direction 13. Ghrelin’s ability to cross the blood-brain barrier is the result of a 
combination of three systems; non-saturable, saturable blood-brain transport and saturable brain-
blood transport, all of which are dependent on the unique post translational acylation and primary 
structure 13-15. In the last 16 years research has demonstrated that ghrelin has various peripheral 
effects and caused a great interest into the manipulation of the ghrelin system as a pharmacological 
tool. Ghrelin has a homeostatic role that encompasses multiple areas of the body, with actions that 
include; downregulation of brown adipose tissue thermogenesis16-18, modulation of non-
hypothalamic brain regions producing an increased taste sensation19 and stimulation of gastric 
emptying and motility6, 20. The actions of ghrelin may contribute to the development of T2DM and 
obesity6 however this review will focus, in detail, on three main sites of ghrelin action; the 
hypothalamus, adipose tissue and the pancreas (Figure 1). 
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2.1 Ghrelin & the hypothalamus  
2.1.1 Obesity 
Ghrelin gene expression and plasma ghrelin levels change with food intake, such that in healthy 
humans acylated levels are elevated before feeding and decreased by feeding 21-23. However, during 
prolonged fasting, plasma levels of acyl-ghrelin are not elevated and it is plasma desacyl-ghrelin 
levels that double 24, 25 . Indeed, ghrelin is the only known gastrointestinal hormone whose 
concentration is increased in the blood following calorie restriction. Ghrelin is often termed ‘the 
hunger hormone’ and is an appetite stimulatory peptide 26. The mechanism by which ghrelin 
stimulates feeding is well documented, the route of stimulation has been linked to ghrelin’s 
activation of Neuropeptide Y (NPY) neurons and agouti- related peptides (AGRP). NPY and AGRP 
containing neurons are located in the ARC where they are activated by elevation of intracellular 
calcium via phospholipase C/protein kinase C and adenylate cyclase/protein kinase A pathways 27. In 
rodents, this calcium influx has also been linked to ghrelin’s activation of phosphoinositide 3-kinase 
(PI3K) pathway due to the enhanced phosphorylation of Akt-Ser 473 28. As well as the activation of 
orexigenic neurons, neurons containing anorexigenic peptides (pro-opiomelanocortin) are 
suppressed in the presence of ghrelin 22, 29, 30. Ghrelin’s role in stimulating feeding is reported to be 
the direct effect of circulating ghrelin on the hypothalamus, as orexigenesis is present without intact 
vagal afferent signalling 31. However, there are reports suggesting that vagotomy does result in the 
loss of ghrelin’s orexigenic function 32. This indicates that peripheral ghrelin induces an eating 
stimulatory effect via an intertwined relationship involving the afferent vagus nerve and direct 
endocrine signalling. The cross comparison of published findings, with respect to ghrelin’s paracrine 
vs endocrine signalling method, does require caution in interpretation as alternative results may 
represent varying methodologies. Several published studies have reported an association between 
ghrelin and obesity with a main focus on plasma ghrelin levels being negatively correlated with body 
mass index (BMI) 29. As well as in obese patients, total ghrelin levels are reduced in obese patients 
with T2DM and levels does not fluctuate throughout the day. Therefore, the total ghrelin 
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concentration does not return to baseline level as it does in lean patients after feeding 11, 33, 34. The 
obese state has attenuated ghrelin levels resulting in abnormal hunger scores, upon the 
administration of acyl-ghrelin in humans, hunger profiles within obese subjects are returned to that 
of lean subjects 35. The supressed level of ghrelin within diet induced obesity (DIO) can be linked to 
the decline in the expression of ghrelin and MBOAT4 in the stomach and GHS-R expression in the 
hypothalamus of mice 36. DIO also has a detrimental effect on the neuroendocrine ghrelin system 
and causes ghrelin resistance in rodents through the down regulation and dysfunction of NPY/ AGRP 
neurons 36. The apparent species-dependent discrepancy in DIO-induced ghrelin resistance warrants 
further research and may prevent the ghrelin system being a useful therapeutic target in DIO 37.   
2.1.2 A role for ghrelin in human obesity? 
Obesity is a multifactorial disease and its origin can span from various avenues including genetics. 
Genetic factors are strongly associated with obesity and cover two areas, monogenic and polygenic 
factors. Prader- Willi syndrome (PWS) is a key example of genetic obesity and is the result of a loss of 
paternal genes in the q11-13 region of chromosome 15. Patients with PWS experience excessive 
appetite (hyperphagia) which is linked to hyperghrelinemia 38. PWS patients have increased fasting 
and post prandial ghrelin levels when compared to non PWS obese or lean patients 38. This indicates 
a potential role for ghrelin as a cause of hyperphagia and obesity in PWS due to either an increase in 
ghrelin gene expression, a decline in transcription inhibitory factors or a reduction in ghrelin 
clearance 39. The inhibition of the ghrelin system may allow for the treatment of individuals 
diagnosed with PWS. This may be achieved by i) ghrelin immunization, ii) MBOAT4 or GOAT 
inhibition, or iii) antagonizing GHS-R.  
Zorrilla et al, demonstrated that ghrelin immunization through a vaccine approach produced a 
significant reduction in weight through metabolic efficiency rather than altering hyerphagia 40. 
Further immunizations were carried out through the use of Spiegelmers, a single stranded mirror 
image oglionucleotide which binds to ghrelin to decrease its half-life 37, 41. However, the use of 
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Spiegelmers only generated weight reduction on a short term basis 41. Preventing the acylation of 
ghrelin through either the reduction in MBOAT4 transcription or GOAT function will allow for a 
decrease in circulating acyl-ghrelin. The use of an antagonist of the GHS-R, [D-Lys3]GHRP-6, has been 
shown in male mice to allow for an increase in glycaemic control and decrease in body weight 42. The 
reduction in glucose levels was mirrored by a decrease in insulin levels, indicating that GHS-R 
antagonism may be a therapeutic pathway for treating both obesity and insulin resistance 42, 43.  
Controversially, an antagonist is only efficacious when blocking the action of an agonist, yet, as 
previously mentioned, the low levels of circulating ghrelin present in obese subjects may invalidate 
this approach. However, further work has led to the development of GHS-R1α inverse agonists that 
work on the principle that GHS-R1α signals ~50% activity, independent of the presence of ghrelin 44. 
The following inverse agonists; [D-Arg-1, D-Phe5, D-Trp7,9, Leu 11]- substance P, which prevent 
constitutive GHS-R1α activity, were administered intracerebroventricularly in rats, resulting in a 
reduction in food intake and weight gain 45. Han Lee, and colleagues also noted that the neuronal 
depletion of GHS-R abolished ghrelin-induced food intake and was detrimental to the development 
of DIO 46. These finding indicate that GHS-R is a key modulator in energy metabolism and plays a role 
in DIO. We propose that further research is needed to elucidate the possible adipogenic and 
lipogenic role of constitutive GHS-R1α signalling in the context of human obesity.  
2.2 Ghrelin & Adipocytes 
2.2.1 Adipogenesis 
Ghrelin is involved in the regulation of metabolic hormones, with GHS-R’s present within adipose 
tissue 4, 47.  In addition to stimulating growth hormone (GH) secretion and appetite, ghrelin has been 
shown to play a role in adiposity. Adipogenesis is a regulated process involving the differentiation of 
pre-adipocytes into mature adipocytes. This is controlled by specific transcription factors; 
peroxisome proliferator-activated receptor γ (PPARγ) and sterol-regulatory element binding protein-
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1 (SREBP1). SREBP1 is encoded by the SREBF1 gene which is transcribed into two splice variants, 
SREBP1-a and SREBP1-c 48. Upon the addition of acyl-ghrelin and desacyl-ghrelin, PPARγ and SREBF1 
mRNA expression levels increase in human visceral adipocytes during differentiation 11. Therefore, in 
the presence of ghrelin, in vitro and in vivo studies have demonstrated that mRNA levels of PPARγ 
are increased resulting in the differentiation and proliferation of preadipocytes 11. PPARγ activity can 
be influenced by key components that play a role in the mammalian insulin pathway, for example; 
mammalian target of rapamycin complex 1 (mTORC1) and the Akt/ Protein kinase B (Akt/PKB) 
complex 27. In the presence of acyl-ghrelin, mTORC1 and Akt/PKB can enhance PPARγ activation 
promoting adipogenesis 27. The presence of mTORC1 and Akt/PKB highlights ghrelin’s ability to have 
multifactorial effects, with the synergy of acyl-ghrelin’s adipogenic effect and insulin signalling. Both 
desacyl and acyl-ghrelin produce an increase in adipogenesis and a decrease in insulin sensitivity, 
however desacyl-ghrelin’s role is not consistent across studies (Table  1) 27.  The elevation of SREBF1 
was accompanied by a significant increase in lipid accumulation in visceral adipocytes 11. This 
administration of ghrelin directly stimulated intracytoplasmic lipid accumulation via the increased 
production of various fat storage promoting enzymes including carboxylase, acetyl CoA, fatty acid 
synthase and lipoprotein lipase 11.   
2.2.2 Lipid retention 
Following chronic intravenous administration in mice, ghrelin has also been shown to increase mRNA 
expression of genes which promote the retention of cholesterol 49. The reverse cholesterol transport 
pathway, the removal of excess cholesterol from peripheral tissues back to the liver for excretion 
and catabolism, is critical due to the pathways role in defence against atherosclerosis 50-52. This 
cholesterol efflux is dependent upon the ATP binding cassette (ABC)A1 and ABCG1 50, 53. ABCG1 and 
ABCA1 are members of a superfamily of transporters that functions to transport cholesterol to the 
cell surface for removal by high density lipoproteins (HDL) 50, 52. PPARγ induces the expression of ABC 
via nuclear cholesterol sensors, liver X receptors (LXR) i.e. LXRα and LXRβ 52. LXR acts as a 
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transcription regulator for the genes associated with cholesterol efflux, which is activated when total 
cellular cholesterol levels are high 54. However, when total cellular cholesterol levels are low, SREBP 
induces cholesterol biosynthesis 54.  So in the presence of ghrelin, SREBP1-c expression is increased 
whilst ABCG1 and LXRβ expression is decreased 49. Even though these results indicate ghrelin has a 
role in increasing lipid retention within adipocytes, the relationship between cholesterol efflux, 
biosynthesis genes and ghrelin is disputed among studies. The hypothalamic activation of GHS-R1α 
in mice and rats results in the activation of Sirtuin 1 (SIRT1) to deacetylate the tumour suppressor 
gene p53, increasing phosphorylation of AMP-activated protein kinase (AMPK) which in turn 
inactivates fatty acid biosynthesis and activates fatty acid oxidation 55-57. In vivo, administration of 
ghrelin to p53 null mice demonstrates a decrease in lipid metabolism modulating gene expression 
i.e. SREBP1c, indicating that p53 is essential for the action of ghrelin on adipose tissue 55.  Ghrelin 
administration has also been reported to activate the PPARγ-LXR-ABC pathway in a dose dependant 
manner, where ghrelin results in an increase in LXR and ABC expression in human THP-1 
macrophages 58. An increase within cellular fat mass could result in an increase in lipogenesis and 
substrate uptake and a decrease in lipolysis and export 1. These processes could alter the intrinsic 
regulation of free fatty acids and cholesterol biosynthesis pathways that could lead to 
hypertriglyceridemia and other complications 59. Due to the diversity of published data and various 
doses of acyl-ghrelin administered, further research into ghrelin mediated lipid retention especially 
within humans is needed.  
2.3 Ghrelin & the pancreas 
2.3.1 Glucose homeostasis 
The process of glucose homeostasis is dependent on the liver and gut as sources for circulating 
glucose and adipose tissue as a peripheral organ for glucose utilisation. Ghrelin and GHS-R1α RNAs 
are expressed within the pancreas and β-cells, suggesting a possible relation for ghrelin in affecting 
glucose homeostasis via insulin function. In humans acyl-ghrelin has direct metabolic actions at a 
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peripheral level, influencing endopancreatic function and altering glucose’s diabetogenic action 60, 61. 
As well as acyl-ghrelin, desacyl-ghrelin has been shown to alter glucose metabolism, the intravenous 
administration of desacyl-ghrelin in humans has been demonstrated to promote a favourable 
influence on glucose metabolism, insulin sensitivity and the inhibition of lipolysis 60, 61. The 
expression of GHS-R and ghrelin within the pancreas suggests local regulation of insulin secretion 62, 
63, with acyl-ghrelin supressing insulin secretion both in vivo and in vitro. Dezaki and colleagues 64 
reported that endogenous acyl-ghrelin supresses insulin secretion via a restriction on glucose 
induced cytosolic calcium concentration and insulin release within islet β cells of mice and rats. 
Furthermore, ghrelin inhibits glucose-induced membrane excitability, supressing cellular signalling 64. 
However, the mechanism in which acyl-ghrelin regulates pancreatic islet function remains unclear 
with few studies in humans. Ghrelin’s role in the attenuation of glucose stimulated insulin secretion 
was elucidated recently, indicating that ghrelin action on β cells may be through a non-direct 
manner. DiGruccio and colleagues demonstrated that the presence of GHS-R1 on δ cells mediated 
indirect ghrelin action on β cells 65. Thus, GHS-R1a+ δ cells, promoted the secretion of intermediate 
products such as somatostatin through a calcium ion cascade that blocked insulin secretion 65.   
Studies in humans has shown that the acute intravenous administration of acyl-ghrelin via bolus 
injection and infusion are associated with an increase in plasma glucose levels in both healthy and 
obese patients, and this ghrelin mediated increase was seen to enhance second phase insulin 
response 8, 26, 66, 67. In fasted mice this direct, non GH-mediated hyperglycaemic effect was blunted by 
the oral administration and intraperitoneal injection of a GHS-R antagonist, stabilising blood glucose 
levels 68. Broglia et al 26 noted that acyl-ghrelin’s initial stimulation of somatostatin levels caused an 
inhibition of insulin release. Further work by Arosio and colleagues 69 noted a similar relationship 
between acyl-ghrelin, somatostatin and glucose metabolism. However, the simultaneous rise in 
somatostatin and glucose indicates that ghrelin’s effect on glucose metabolism is still unclear. The 
effect of ghrelin is suggested to be direct yet the query remains as to whether this effect is via the 
promotion of glycogen breakdown and/or the inhibition of glucose uptake. Upon longer term 
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administration of acyl-ghrelin in healthy men, at a constant infusion rate lasting 180 minutes at 5 
pmol/Kg, glucose levels were raised but glucose-induced insulin secretion was blocked, with the 
blockage only being restored when ghrelin supply ceased 70. However, acyl-ghrelin infusion in 
healthy humans caused peripheral insulin resistance post administration raising the possibility that 
insulin resistance may be attributed to raised GH and free fatty acid (FFA) secretion 63.  
 The literature indicates that acyl-ghrelin plays a detrimental role in glucose homeostasis, 
however studies indicate that desacyl-ghrelin plays a beneficiary role. In rodents and humans, 
desacyl-ghrelin was proven to enhance insulin levels in response to glucose load and shown to 
counteract acyl-ghrelins diabetogenic effect 71-73. This a role for desacyl-ghrelin as a potent 
secretagogue reiterates the importance to consider desacyl and acyl-ghrelin as separate entities and 
a possible therapeutic pathway may lie within the desacyl-ghrelin and acyl-ghrelin ratio.   
2.3.2 A role for ghrelin in type 2 diabetes? 
An important contributor to the pathophysiology of T2DM is the failure of glucose uptake into the 
peripheral tissues such as adipose, skeletal muscle and liver. Decreased ghrelin levels within patients 
with T2DM are associated with an increase in abdominal adiposity and insulin resistance 74. As 
previously mentioned ghrelin has a demonstrated role in fat metabolism and glucose homeostasis, 
and cross talk between lipid and glucose metabolism may result in a physiological role for ghrelin in 
insulin resistance. Cellular lipid accumulation that is observed upon ghrelin administration will have 
a knock on effect on glucose homeostasis. There are two hypothesese in place regarding lipid 
mediated insulin resistance. The first is an excess of visceral adiposity triggers the release of FFA into 
the circulation. An increase in hepatic FFA oxidation triggers insulin resistance and an increase in 
glucose output from the liver 75, 76. Acyl-ghrelin infusion in humans has been associated with a rise in 
circulating FFA levels 35, this could result in a decrease in insulin sensitivity 76. These findings suggest 
a causative role in the reported insulin resistance that occurs in healthy volunteers when given an 
acyl-ghrelin infusion 70, 77. The second hypothesis is related to enlarged fat laden adipocytes 
12 
 
associated with release of FFA, physical stress and reactive oxygen species (ROS) production 78, 79. 
Prolonged elevation of ghrelin increases visceral adiposity in mice and attenuates the transcription 
of LXRβ and ABCG1 which increases adipocyte volume due to a reduction in lipid export 49. LXR 
isoforms have been reported to have anti-inflammatory properties, LXR ligand activation causes the 
inhibition of NFκB dependant induction of inflammatory genes 80. This could allow for altered 
immune function, due to an increase in ROS and the release of damaging inflammatory agents such 
as tumor necrosis factor α (TNFα).  When Lxrab-/-  mice are placed under bacterial lipid peroxidase 
stress there is an increase in the expression of interlukin 1β, TNFα  and nitric oxide synthase 81.  
This indirect immuno-modulatory response may lead to insulin resistance and T2DM due to TNFα 
ability to induce the inhibitory phosphorylation of insulin receptor substrate (IRS)-1, leading to 
systemic insulin resistance 79. The association between obesity and T2DM is well documented, 
allowing for ghrelin signalling to play a potential pharmacological role in its prevention and/or 
treatment. YIL-781  is a piperidine substituted quinazolinone derivative with a selective affinity for 
GHS-R1α, it is a competitive antagonist for GHS-R1α resulting in the blockage of the ghrelin binding 
domain 82. Upon YIL- 781 oral administration at 3 mg/kg to insulin resistant DIO rats it was shown to 
reduce fat mass, enhance glucose stimulated insulin secretion and promote weight loss 82. Ghrelin’s 
ability to cause hyperglycemia through GHS-R1α could underpin a therapeutic pathway that can 
alter insulin secretion and prevent glucose intolerance in T2DM 68. The attenuation of rat islet β cells 
in the presence of ghrelin indicates that a ghrelin blockade may result in an increase in previously 
supressed glucose-induced insulin release. This will enable pancreatic islets to function at a higher 
yield, producing more insulin and restoring the body to normoglycemia 83. However, the published 
data regarding the mechanism between ghrelin and insulin secretion is varied within humans. Tong 
et al 84, infused 12 healthy volunteers with ghrelin at 0.3, 0.9 or 1.5 nmol/kg/h, and show that ghrelin 
can reduce glucose stimulated insulin secretion. The range of ghrelin in this study fall within the 
physiological range in the circulation which may not be a true representative of the lower 
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concentration of ghrelin found in β cells 85. Further insight in humans or human cells need to be 
explored in order to investigate species-dependent effects.  
Exploration of novel research into ghrelin’s relationship with obesity, lipid retention and glucose 
homeostasis may elucidate novel strategies to treat and prevent T2DM. As well as therapeutic 
avenues in T2DM, the treatment must take into consideration the physiological roles that ghrelin has 
in other regions of the body. The blocking of GHS-R1α may seem beneficial for obesity but may 
cause detrimental effects in other organs. Recently published data demonstrates that ghrelin has an 
AMPK-dependent protective role in substantia nigra dopamine neurons in a mouse model of 
Parkinson’s disease 86. Furthermore, acyl-ghrelin promotes new neurone formation and enhances 
cognition in the brains of adult rodents 87, 88. With ghrelin reported to have effects on multiple 
organs in the body it is clear that new ghrelin-based therapies for T2DM need to consider potential 
adverse consequences, particularly for brain function.       
 
3 Future work 
In order to establish a possible therapeutic role for ghrelin within human obesity and T2DM previous 
research findings must be amalgamated and developed further to delineate ghrelin-specific 
pathways. The examination of the use GHS-R1α inverse agonist to prevent DIO will require the 
optimisation of dosage to ensure that blocking the receptor will not have detrimental effects on the 
other important actions of ghrelin.  An in vitro study in human adipocytes would determine the 
effect that a physiological range of desacyl and acyl-ghrelin has on lipid retention and would allow 
for the molecular characterisation of this effect. This will lead to a better understanding of the 
cellular mechanisms involved, potentially leading to novel treatments for complications associated 
with atherosclerosis and hypertriglyceridemia.  For instance, translating previous findings by Davies 
and colleagues 49,  is important as it could provide evidence for the speculation that ghrelin 
immunization may prevent lipid retention within adipocytes. As previously mentioned the resultant 
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fat laden adipocytes could be detrimental and result in the development of T2DM, so in essence we 
envision that the prevention of lipid accumulation within adipocytes will prevent the indirect 
immune modulating response that may be leading to insulin resistance and T2DM. In addition, this 
area of research requires further insight into whether the effect of ghrelin on adipocytes is 
dependent on acylation of the hormone. 
 4 Summary 
This review considers the important roles that ghrelin plays in regulating lipolysis, lipogenesis and 
adipogenesis within adipocytes. However, the studies compared in this review were performed in 
different species and predominantly in rodents. Further work is essential to understand the role of 
ghrelin in cellular energy balance within human adipocytes. Current literature report variations in 
route of administration, dosage and model species, allowing for the potential misinterpretation of 
ghrelin’s physiological role. An expansion of this work using healthy and diseased humans and 
human cellular models treated with physiological levels of acyl and desacyl-ghrelin will increase our 
current knowledge of the pathways associated with glucose and lipid metabolism. Human studies 
will also allow for the elucidation of the therapeutic potential of ghrelin in various metabolic 
disturbances but in particular, DIO and its complications.  
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Figure 1. Ghrelin peripheral effects on specific tissues.  
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Model Dose Treatment Effect  Reference 
Healthy humans 1 μg/kg  
Acyl ghrelin  
Intravenous Decreased Insulin 
Sensitivity 
Reduced serum 
insulin levels 
26
 
Healthy humans Bolus;  
Des acyl ghrelin 
[1.1 µg/kg] 
IV;  
Des acyl ghrelin 
[4.0 µg/kg/h] 
 
Bolus injection followed 
by continuous 
intravenous infusion 
Des acyl ghrelin 
had no effect on 
insulin secretion 
89
 
Male C57BL/6 
mice 
5 nmol/day  
Des acyl ghrelin 
& Acyl ghrelin 
Chronic 
intracerebroventricular 
infusion  
Hyperinsulinemia 
90
 
Human 
macrophages 
(THP-1) 
1, 10 & 100 nM 
ghrelin  
Treated PMA-
differentiated THP-1 
macrophages with 
increasing doses of 
ghrelin  
Promotes 
activation of the 
Akt/PKB pathway 
 
58
 
3T3-L1 Acyl ghrelin 1-
100 pmol, 
Des Acyl ghrelin 
1-100 pmol  
Preadipocytes incubated 
with des acyl ghrelin and 
acyl ghrelin for 24 hours 
DAG and AG 
stimulated 
adipogenesis, fatty 
acid uptake and 
inhibited lipolysis 
91
 
C57BL/6NHsd 
mice 
100 nM Ghrelin Wild type mouse 
pancreatic islets 
incubated with ghrelin  
Reduced glucose 
stimulated insulin 
secretion 
65
 
Table 1. Effects of ghrelin treatment on insulin secretion and adipogenesis.  
 
